A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma - Nassar, Amin H.; Mouw, Kent W.; Jegede, Opeyemi; Shinagare, Atul B.; Kim, Jaegil; Liu, Chia-Jen; Pomerantz, Mark; Harshman, Lauren C.; Van Allen, Eliezer M.; Wei, Xiao X.; McGregor, Bradley; Choudhury, Atish D.; et al. (British journal of cancer, 2020)
Keywords: 692/4028/67/589/1336; 692/53/2423; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - immunology; Biomedical and Life Sciences; Biomedicine; Bladder cancer; Cancer Research; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - genetics; Carcinoma, Transitional Cell - immunology; Drug Resistance; Epidemiology; Female; Genomics; Humans; Immune checkpoint inhibitors; Lymphocyte Count; Lymphocytes; Male; Metastases; Metastasis; Middle Aged; Molecular Medicine; Neutrophils - immunology; Oncology; PD-1 protein; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Taxanes; Tumors; Urologic Neoplasms - drug therapy; Urologic Neoplasms - genetics; Urologic Neoplasms - immunology; Urothelial carcinoma